1

Search

Eli Lilly (LLY) Share Price Target 2026, 2027, 2028, 2030: Bear, Base & Bull Cases

  • Share this:

Eli Lilly (NYSE: LLY) price as of 20 Nov 2026 close: $1,347.11.

Eli Lilly has become the world's most valuable pharmaceutical company, thanks to its diabetes and obesity medicines Mounjaro and Zepbound. Together they generated more than $16 billion of sales in a single quarter, and Lilly has now launched a once-daily obesity pill.

Lilly's revenue is growing close to 40% a year — extraordinary for a large drugmaker — but the stock already trades at a premium valuation. This article explains how Lilly makes money and sets out an Eli Lilly share price target for 2027 to 2030.

1. Eli Lilly share price target 2027–2030 at a glance

All three scenarios come from one transparent formula, explained in the method section below. Targets are for the end of each calendar year.

Year-endBear ($)Base ($)Bull ($)
20279401,3101,500
20281,0101,5501,860
20291,1001,8302,310
20301,1802,1602,860

The base case implies a price change of roughly 12% a year from today's $1,347.11 to the end of 2030, before dividends.


2. How Eli Lilly makes money

Lilly's revenue comes from several therapy areas:

  • Diabetes and obesity (cardiometabolic health): Mounjaro (tirzepatide for type 2 diabetes), Zepbound (tirzepatide for obesity), Trulicity and the new oral GLP-1 Foundayo. This is now the majority of revenue and the main growth driver.
  • Oncology: Verzenio (breast cancer), Jaypirca and other cancer treatments.
  • Immunology: Taltz (psoriasis), Omvoh (ulcerative colitis) and Ebglyss (eczema).
  • Neuroscience: Kisunla, an Alzheimer's disease treatment.

How tirzepatide works: it mimics two gut hormones (GLP-1 and GIP) that regulate blood sugar and appetite, leading to significant weight loss. Demand has been so strong that Lilly has spent tens of billions of dollars building new manufacturing plants.

Why it matters for the targets: Lilly's earnings depend on how fast obesity treatment grows, how much prices fall as insurers and governments negotiate, and the success of next-generation drugs such as retatrutide. Volume grew 53% last quarter while realised prices fell 15% — a pattern likely to continue as access widens.


3. Latest results: what changed

Q3 2026ValueChange (YoY)
Revenue$24.4 billion+39%
Mounjaro sales$10.7 billion+65%
Zepbound sales$5.4 billion+48%
Volume growth—+53%
Realised price—−15%
2026 revenue guidance$91–92 billionRaised

Revenue rose 39% to $24.4 billion, driven by a 53% increase in volume, partly offset by a 15% fall in realised prices. Mounjaro sales grew 65% to $10.7 billion and Zepbound 48% to $5.4 billion. The new oral drug Foundayo added $184 million in its launch quarter.

Lilly raised its 2026 revenue guidance to $91–92 billion from $85–87 billion but trimmed its adjusted EPS guidance slightly to $35–36 because of charges for acquired research projects. It also reported positive Phase 3 results for retatrutide versus Ozempic in type 2 diabetes.


4. How we calculate the Eli Lilly share price targets

Target = projected EPS × P/E multiple. We start from the forward EPS of $46.94 implied by the current forward P/E, treat it as FY2027 EPS, and grow it at each scenario's rate for later years. Each year-end target applies a P/E multiple to that year's EPS. Read our full methodology.

  • Starting EPS: about $46.94, implied by a 28.7× forward P/E.
  • Bear case: EPS grows 8% a year, P/E 20×. Price cuts and competition slow growth; the multiple falls toward the sector average.
  • Base case: EPS grows 18% a year, P/E 28×. Volumes keep surging while prices decline gradually; the multiple stays close to today's forward level.
  • Bull case: EPS grows 24% a year, P/E 32×. Oral drugs and retatrutide extend Lilly's lead; the market keeps paying a growth premium.
Financial yearBear EPS ($)Base EPS ($)Bull EPS ($)
FY202746.9446.9446.94
FY202850.7055.3958.21
FY202954.7565.3672.17
FY203059.1377.1289.50

Worked example (base, 2027): $46.94 = $46.94 FY2027 EPS → × 28 = $1,310.

Sensitivity — 2030 base-case EPS of $77.12 at different multiples:

P/E20×28×32×
2030 price ($)1,5402,1602,470

The sensitivity table shows why the multiple matters as much as earnings: the same 2030 profit can justify very different prices depending on how much investors are willing to pay for it.


5. Eli Lilly share price in 2026: where it stands

With only weeks left in 2026, a year-end "target" is not meaningful. The stock was at $1,347.11 on 20 Nov 2026, within a 52-week range of $850.51 – $1,475.25. The stock is about 9% below its 52-week high.


6. Eli Lilly share price target 2027: $940 – $1,500 (base $1,310)

Based on FY2027 EPS of $46.94 / $46.94 / $46.94 (bear / base / bull). What to watch: Volume growth for Mounjaro and Zepbound as prices fall.


7. Eli Lilly share price target 2028: $1,010 – $1,860 (base $1,550)

Based on FY2028 EPS of $50.70 / $55.39 / $58.21 (bear / base / bull). What to watch: Uptake of Foundayo, the oral GLP-1.


8. Eli Lilly share price target 2029: $1,100 – $2,310 (base $1,830)

Based on FY2029 EPS of $54.75 / $65.36 / $72.17 (bear / base / bull). What to watch: Retatrutide approval timeline.


9. Eli Lilly share price target 2030: $1,180 – $2,860 (base $2,160)

Based on FY2030 EPS of $59.13 / $77.12 / $89.50 (bear / base / bull). What to watch: US drug-pricing policy and Medicare coverage of obesity drugs.


10. Key metrics

Lilly trades at a large premium to other big drugmakers because its growth is far faster.

MetricValueWhy it matters
Forward EPS (est.)~$46.94Starting point
Trailing P/E43.7×Very high
Forward P/E28.7×Prices in strong growth
Q3 revenue growth+39%Exceptional for big pharma
2026 adjusted EPS guide$35–36Includes R&D charges

11. Dividends and shareholder returns

Lilly pays a quarterly dividend and has increased it every year for more than a decade, typically by around 15%. Because the share price has risen so much, the yield is below 1%.

Lilly is investing heavily in manufacturing capacity and research, so most of its cash goes back into the business. Shareholder returns depend mainly on earnings growth.


12. How it compares with other US large caps

CompanyPrice ($)Trailing P/EForward P/E52-week range ($)
Netflix (NFLX)56.7316.4×15.8×56.56 – 111.10
JPMorgan Chase (JPM)310.5313.0×12.4×279.10 – 366.50
Broadcom (AVGO)304.4138.9×17.5×289.77 – 495.00
Eli Lilly (LLY)1,347.1143.7×28.7×850.51 – 1,475.25
Visa (V)401.8732.9×26.7×293.89 – 442.23

Prices as of 20 Nov 2026 close. The companies are in different industries, so the table is a valuation snapshot rather than a like-for-like comparison. For more US targets see Nvidia, Microsoft and Apple.


13. The key debate on Eli Lilly

The bull argument: Lilly leads the fastest-growing market in pharmaceuticals, with the most effective approved obesity drug, a new oral pill and a strong pipeline led by retatrutide. Revenue is growing almost 40% a year, and obesity treatment is still in its early stages globally.

The bear argument: Prices are falling quickly as access widens, competition from Novo Nordisk and new entrants is growing, and governments are pressuring drug prices. At almost 29× forward earnings, the stock already assumes that Lilly keeps its lead for years.

How to tell which side is winning: Watch volume growth versus price declines. If volumes keep rising faster than prices fall, the base and bull cases hold; slowing volumes would point to the bear case.


14. Risks that would break the base case

  • Faster price cuts from US policy or insurer negotiations.
  • Competition from Novo Nordisk, Amgen and other obesity drug developers.
  • Safety concerns or regulatory setbacks.
  • Manufacturing problems limiting supply.
  • Patent challenges in the long term.

15. What the numbers suggest

Our base case of $2,160 by 2030 assumes 18% annual EPS growth and a 28× multiple. Because the stock already trades at a premium, the 2027 base target is close to today's price, with gains building in later years. The bull case ($2,860) needs Lilly to extend its lead; the bear case ($1,180) shows what happens if growth slows sharply.

Who might consider Eli Lilly: long-term investors who want exposure to the obesity and diabetes treatment market and accept that the shares can swing sharply on trial results, pricing news or competitor data. Because the valuation is already high, patience is important: most of the base-case gain comes in 2028–2030.

This is a framework, not a recommendation. Your own decision should depend on your time horizon, risk tolerance and existing holdings.


16. FAQs on the Eli Lilly share price

What is the Eli Lilly share price target for 2027?
Our base case is $1,310, assuming 18% annual EPS growth and a 28× P/E. The range is $940 (bear) to $1,500 (bull).

What is the Eli Lilly share price target for 2030?
Base case $2,160; range $1,180 to $2,860. It assumes FY2030 EPS of about $77.12.

What are Mounjaro and Zepbound?
Both contain tirzepatide. Mounjaro is approved for type 2 diabetes and Zepbound for obesity.

What is Foundayo?
Lilly's once-daily oral GLP-1 obesity medicine, launched in 2026.

Does Eli Lilly pay a dividend?
Yes, quarterly, but the yield is below 1%.

What is retatrutide?
An experimental drug that targets three hormone receptors. It has shown strong results in trials.

How big could the obesity drug market become?
Estimates vary widely, but many analysts expect global sales of obesity medicines to reach well over $100 billion a year by the early 2030s as more patients gain access and oral versions launch.

About this analysis: Prepared by the ChartMyWealth Editorial Team using the scenario method described in our methodology. Prices and results were reviewed on 20 Nov 2026, and targets are reviewed after each results announcement.

Disclaimer: This article is for educational purposes only and is not investment advice or a recommendation to buy or sell any security. Price targets are scenario estimates based on the stated assumptions and may not materialise. Please consult a licensed financial adviser before making investment decisions.

ChartMyWealth Editorial Team

ChartMyWealth Editorial Team

The ChartMyWealth Editorial Team analyses Indian and US listed companies using their reported results, exchange filings and market data. Every share price target shows its formula, assumptions and sources, with bear, base and bull scenarios, and is updated after quarterly results.

Leave a comment

Your email address will not be published. Required fields are marked *

Your experience on this site will be improved by allowing cookies. Cookie Policy